Merck Highlights Robust Oncology, Hematology Pipeline With Four Agents in Phase III Trials
Trials will evaluate four novel agents for cancers that include essential thrombocythemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, non-small cell
READ MORE